00:49:03 EST Sun 05 Dec 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:ANVS from 2020-12-04 to 2021-12-03 - 85 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2021-11-15 09:01U:ANVSNews ReleaseAnnovis Bio Announces Transfer of Listing to the New York Stock Exchange
2021-11-12 10:27U:ANVSNews ReleaseAnnovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference
2021-11-09 08:31U:ANVSNews ReleaseAnnovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
2021-11-02 08:31U:ANVSNews ReleaseAnnovis Bio to Present at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
2021-10-15 20:56U:ANVSNews ReleaseSHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS
2021-10-13 10:20U:ANVSNews ReleaseKessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Annovis Bio, Inc. Investors in Securities Fraud Class Action Lawsuit
2021-10-09 10:15U:ANVSNews ReleaseROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important October 18 Deadline in Securities Class Action - ANVS
2021-10-07 19:45U:ANVSNews ReleaseSHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS
2021-10-05 08:02U:ANVSNews ReleaseAnnovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease
2021-10-04 17:45U:ANVSNews ReleaseANVS SHAREHOLDER CLASS ACTION LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.
2021-10-04 09:12U:ANVSNews ReleaseANVS Investor Reminder: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Annovis Bio, Inc.
2021-10-01 11:35U:ANVSNews ReleaseThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
2021-09-29 21:23U:ANVSNews ReleaseSHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS
2021-09-25 18:24U:ANVSNews ReleaseDeadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against Annovis Bio, Inc.
2021-09-25 10:18U:ANVSNews Release(ANVS) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel Regarding Leading Annovis Bio Class Action Lawsuit
2021-09-24 09:02U:ANVSNews ReleaseAnnovis Bio to Present at the Cantor Global Healthcare Conference
2021-09-23 19:03U:ANVSNews ReleaseROSEN, A LEADING LAW FIRM, Encourages Annovis Bio, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important October 18 Deadline in Securities Class Action - ANVS
2021-09-21 15:23U:ANVSNews ReleaseINVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm Before October 18, 2021
2021-09-19 22:33U:ANVSNews ReleaseSHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS
2021-09-15 19:28U:ANVSNews ReleaseKessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Annovis Bio, Inc.
2021-09-13 11:10U:ANVSNews ReleasePomerantz Law Firm Announces the Filing of a Class Action Against Annovis Bio, Inc. and Certain Officers - ANVS
2021-09-13 11:00U:ANVSNews ReleaseGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
2021-09-10 09:00U:ANVSNews ReleaseAnnovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-09 13:00U:ANVSNews ReleaseDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
2021-09-08 14:28U:ANVSNews ReleaseANVS CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.
2021-09-07 12:05U:ANVSNews ReleaseThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
2021-09-05 04:15U:ANVSNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS
2021-09-03 08:31U:ANVSNews ReleaseAnnovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
2021-08-28 11:03U:ANVSNews ReleaseANVS CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Annovis Bio, Inc. Shareholders of Securities Fraud Class Action Lawsuit
2021-08-27 15:58U:ANVSNews ReleaseKessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Annovis Bio, Inc.
2021-08-27 15:45U:ANVSNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS
2021-08-26 12:00U:ANVSNews ReleaseINVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2021-08-25 20:00U:ANVSNews ReleaseANVS NOTICE: Investors With Substantial Losses Have Opportunity to Lead the Annovis Bio, Inc. Class Action Lawsuit
2021-08-25 08:32U:ANVSNews ReleaseAnnovis Bio to Present at Biomarkers for Alzheimer's Disease Summit 2021
2021-08-23 23:32U:ANVSNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of San Juan Basin Royalty Trust - SJT
2021-08-22 11:45U:ANVSNews ReleaseANVS NOTICE: ROSEN, A RESPECTED AND LEADING LAW FIRM, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ANVS
2021-08-20 18:09U:ANVSNews ReleaseINVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
2021-08-19 16:05U:ANVSNews ReleaseANNOVIS BIO SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Annovis Bio, Inc. - ANVS
2021-08-19 15:34U:ANVSNews ReleaseANVS Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Annovis Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
2021-08-19 13:15U:ANVSNews ReleaseROSEN, TRUSTED INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline - ANVS
2021-08-19 09:35U:ANVSNews ReleaseANVS DEADLINE: Investors With Substantial Losses Have Opportunity to Lead the Annovis Bio, Inc. Class Action Lawsuit
2021-08-18 20:00U:ANVSNews ReleaseANNOVIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm
2021-08-18 19:05U:ANVSNews ReleaseANVS INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc.
2021-08-11 21:57U:ANVSNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS
2021-08-11 08:31U:ANVSNews ReleaseAnnovis Bio Completes Dosing of Parkinson's Disease Patients with ANVS401 in Phase 2a Clinical Trial
2021-08-04 00:33U:ANVSNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS
2021-07-30 10:08U:ANVSNews ReleaseAnnovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease
2021-07-30 09:07U:ANVSNews ReleaseInvestigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm
2021-07-28 19:32U:ANVSNews ReleaseAnnovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference
2021-07-23 08:33U:ANVSNews ReleaseAnnovis Bio to Present New Data at 2021 Alzheimer's Association International Conference
2021-07-20 08:37U:ANVSNews ReleaseAnnovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study
2021-07-02 08:31U:ANVSNews ReleaseAnnovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials
2021-07-01 08:35U:ANVSNews ReleaseAnnovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO
2021-06-24 08:05U:ANVSNews ReleaseAnnovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards
2021-06-10 08:32U:ANVSNews ReleaseAnnovis Bio to Present at 2021 BIO Digital
2021-06-08 08:32U:ANVSNews ReleaseAnnovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study
2021-06-03 08:33U:ANVSNews ReleaseAnnovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
2021-06-01 08:31U:ANVSNews ReleaseAnnovis Bio's ANVS401 Improves Speed and Accuracy in Alzheimer's and in Parkinson's Patients
2021-05-28 08:32U:ANVSNews ReleaseAnnovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
2021-05-27 11:56U:ANVSNews ReleaseAnnovis Bio, Inc. Announces Closing of $50 Million Public Offering
2021-05-23 17:44U:ANVSNews ReleaseAnnovis Bio, Inc. Announces Pricing of Public Offering
2021-05-21 17:16U:ANVSNews ReleaseAnnovis Bio, Inc. Announces Proposed Public Offering of Common Stock
2021-05-21 08:05U:ANVSNews ReleaseAnnovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
2021-05-20 16:31U:ANVSNews ReleaseAnnovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and Hosted by M-Vest on May 26th, 2021
2021-05-19 16:31U:ANVSNews ReleaseAnnovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients
2021-05-18 08:32U:ANVSNews ReleaseAnnovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research
2021-05-13 08:31U:ANVSNews ReleaseAnnovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome
2021-05-11 06:47U:ANVSNews ReleaseAnnovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
2021-05-10 14:01U:ANVSNews ReleaseAnnovis Bio to Ring Closing Bell at the New York Stock Exchange
2021-05-06 06:46U:ANVSNews ReleaseAnnovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
2021-04-29 07:01U:ANVSNews ReleaseAnnovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
2021-04-15 07:32U:ANVSNews ReleaseAnnovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman
2021-03-17 06:46U:ANVSNews ReleaseAnnovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
2021-03-16 06:46U:ANVSNews ReleaseAnnovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
2021-03-11 07:05U:ANVSNews ReleaseAnnovis Bio, Inc. to present at the Q1 Virtual Investor Summit  
2021-03-11 07:03U:ANVSNews ReleaseAnnovis Bio Signs GMP Manufacturing Agreement to Support Planned Late- Stage Studies
2021-03-10 07:01U:ANVSNews ReleaseAnnovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury
2021-03-09 07:32U:ANVSNews ReleaseAnnovis Bio to Present at the H.C. Wainwright Global Life Sciences Conference
2021-02-16 06:45U:ANVSNews ReleaseAnnovis Bio to Present at the BIO CEO & Investor Digital Conference
2021-02-04 06:46U:ANVSNews ReleaseAnnovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
2021-02-02 06:46U:ANVSNews ReleaseAnnovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
2021-01-05 06:46U:ANVSNews ReleaseAnnovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference
2020-12-17 06:45U:ANVSNews ReleaseAnnovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
2020-12-15 06:45U:ANVSNews ReleaseAnnovis Bio Showcases its Unique Approach to Alzheimer ’s at the New  York  Academy  of  Sciences
2020-12-07 16:05U:ANVSNews ReleaseAnnovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020